Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 10.3% in October

Gossamer Bio, Inc. (NASDAQ:GOSS) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 6,950,000 shares, a decrease of 10.3% from the September 30th total of 7,750,000 shares. Based on an average daily volume of 899,400 shares, the short-interest ratio is currently 7.7 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GOSS shares. Wedbush restated an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, September 17th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Price Performance

Shares of GOSS opened at $0.88 on Friday. Gossamer Bio has a 52 week low of $0.46 and a 52 week high of $1.60. The company has a current ratio of 8.21, a quick ratio of 8.21 and a debt-to-equity ratio of 2.42. The firm has a market cap of $198.63 million, a price-to-earnings ratio of -2.25 and a beta of 1.96. The stock has a 50 day moving average of $0.94 and a 200-day moving average of $0.86.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Monday, August 12th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $95.84 million for the quarter, compared to analysts’ expectations of $160.00 million. As a group, analysts forecast that Gossamer Bio will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors have recently modified their holdings of GOSS. Sequoia Financial Advisors LLC boosted its stake in Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares during the period. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio in the 1st quarter worth approximately $34,000. Financial Advocates Investment Management lifted its holdings in shares of Gossamer Bio by 57.5% in the 2nd quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock worth $96,000 after purchasing an additional 39,000 shares during the last quarter. US Bancorp DE acquired a new position in Gossamer Bio during the 3rd quarter valued at approximately $39,000. Finally, Choreo LLC bought a new position in Gossamer Bio during the 2nd quarter worth $46,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.